| Symbol | ARNI |
|---|---|
| Name | ARNO THERAPEUTICS, INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 97062 United States OR 20550 SW 115th Ave |
| Telephone | (503) 598-6659 |
| Fax | — |
| — | |
| Website | http://www.arnothera.com |
| Incorporation | US |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | Crowe Horwath, LLP; |
| Audit Status | NOT AVAILABLE |
| Reporting Status | Dark: Alternative Reporting Standard |
| CIK | 0001195116 |
| Description | Arno is a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics. The company has exclusive worldwide rights to three innovative clinical stage compounds with unique mechanisms of action that have the potential to be first-in-class products for the treatment of various forms of cancer, including both hematologic malignancies and solid tumors, and other life threatening diseases. The lead compound, onapristone, is an oral, anti-progestin currently in a Phase I/II clinical trial for patients with castration resistant prostate cancer. Additional info from OTC: |
Expert Market symbol attribute type Security_Name was changed. Previous value: -. New value: ARNO THERAPEUTICS INC.
Read moreOTCQX U.S. Premier symbol attribute type Security_Name was changed. Previous value: CONSUMERS BANCORP INC. New value: ARNO THERAPEUTICS INC.
Read more